Bristol-Myers Squibb Company Ce (CELG-RI) Earnings History
Profitable37 years of earnings data (1989–2025) · Positive TTM net income
Loading earnings history...
Bristol-Myers Squibb Company Ce (CELG-RI) Earnings Overview
As of June 21, 2026, Bristol-Myers Squibb Company Ce (CELG-RI) reported trailing twelve-month net income of $7.28B, reflecting +178.5% year-over-year growth. The company earned $3.55 per diluted share over the past four quarters, with a net profit margin of 14.6%.
Looking at the long-term picture, CELG-RI's historical earnings data spans multiple years. The company achieved its highest annual net income of $10.61B in fiscal 2009.
Bristol-Myers Squibb Company Ce maintains positive profitability with a gross margin of 65.9%, operating margin of 31.4%, and net margin of 14.6%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including BMY ($7.28B net income, 14.6% margin), MRK ($18.25B net income, 28.1% margin), PFE ($7.49B net income, 12.4% margin), CELG-RI has outperformed on profitability metrics. Compare CELG-RI vs BMY →
CELG-RI Earnings vs Peers
Earnings metrics vs comparable public companies
CELG-RI Historical Earnings Data (1989–2025)
37 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7.05B | +178.8% | $15.12B | $3.46 | 14.6% | 31.4% |
| 2024 | -$8.95B | -211.5% | $9.66B | $-4.41 | -18.5% | 20.0% |
| 2023 | $8.03B | +26.8% | $8.20B | $3.86 | 17.8% | 18.2% |
| 2022 | $6.33B | -9.5% | $9.10B | $2.95 | 13.7% | 19.7% |
| 2021 | $6.99B | +177.6% | $8.54B | $3.12 | 15.1% | 18.4% |
| 2020 | -$9.02B | -362.1% | $2.18B | $-3.98 | -21.2% | 5.1% |
| 2019 | $3.44B | -30.6% | $5.91B | $2.01 | 13.2% | 22.6% |
| 2018 | $4.95B | +391.8% | $5.12B | $3.03 | 21.9% | 22.7% |
| 2017 | $1.01B | -77.4% | $3.45B | $0.61 | 4.8% | 16.6% |
| 2016 | $4.46B | +174.4% | $4.54B | $2.65 | 22.9% | 23.4% |
| 2015 | $1.62B | -19.0% | $1.73B | $0.97 | 9.8% | 10.4% |
| 2014 | $2.00B | -21.8% | $1.71B | $1.20 | 12.6% | 10.8% |
| 2013 | $2.56B | +30.8% | $2.93B | $1.54 | 15.6% | 17.9% |
| 2012 | $1.96B | -47.2% | $3.93B | $1.16 | 11.1% | 22.3% |
| 2011 | $3.71B | +19.6% | $6.65B | $2.16 | 17.5% | 31.3% |
| 2010 | $3.10B | -70.8% | $5.61B | $1.80 | 15.9% | 28.8% |
| 2009 | $10.61B | +102.2% | $5.74B | $5.37 | 56.4% | 30.5% |
| 2008 | $5.25B | +142.4% | $4.24B | $2.62 | 25.5% | 20.6% |
| 2007 | $2.17B | +36.6% | $3.53B | $1.09 | 11.2% | 18.2% |
| 2006 | $1.58B | -47.2% | $2.62B | $0.81 | 8.8% | 14.6% |
| 2005 | $3.00B | +25.6% | $3.95B | $1.51 | 15.6% | 20.6% |
| 2004 | $2.39B | -23.1% | $4.46B | $1.21 | 12.3% | 23.0% |
| 2003 | $3.11B | +50.3% | $4.95B | $1.59 | 14.9% | 23.7% |
| 2002 | $2.07B | -60.6% | $4.29B | $1.02 | 11.4% | 23.7% |
| 2001 | $5.25B | +11.3% | $6.25B | $2.67 | 27.0% | 32.2% |
| 2000 | $4.71B | +13.1% | $5.99B | $2.36 | 25.9% | 32.9% |
| 1999 | $4.17B | +32.7% | $5.85B | $2.06 | 20.6% | 28.9% |
| 1998 | $3.14B | -2.0% | $5.12B | $1.55 | 17.2% | 28.0% |
| 1997 | $3.21B | +12.5% | $4.44B | $1.57 | 19.2% | 26.6% |
| 1996 | $2.85B | +57.3% | $3.95B | $1.40 | 18.9% | 26.2% |
| 1995 | $1.81B | -1.6% | $3.62B | $0.89 | 13.2% | 26.3% |
| 1994 | $1.84B | -6.0% | $3.22B | $0.90 | 15.4% | 26.9% |
| 1993 | $1.96B | -0.2% | $2.40B | $0.95 | 17.2% | 21.1% |
| 1992 | $1.96B | -4.6% | $1.96B | $0.96 | 17.6% | 17.6% |
| 1991 | $2.06B | +17.6% | $2.77B | $0.99 | 18.4% | 24.8% |
| 1990 | $1.75B | +134.0% | $2.39B | $0.84 | 17.0% | 23.2% |
| 1989 | $747M | - | $1.08B | $0.36 | 8.1% | 11.8% |
Download Data
Export CELG-RI earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
37+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CELG-RI — Frequently Asked Questions
Quick answers to the most common questions about buying CELG-RI stock.
What is CELG-RI earnings per share (EPS)?
CELG-RI trailing twelve-month (TTM) diluted EPS is $3.55, reflecting +178.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1989 to 2025 is available in the table on this page.
What is Bristol-Myers Squibb Company Ce's net income?
Bristol-Myers Squibb Company Ce (CELG-RI) trailing twelve-month net income is $7.3B as of 2025. Earnings grew +178.5% year-over-year.
Is CELG-RI profitable?
Yes, CELG-RI is profitable with a TTM net income of $7.3B and a net profit margin of +14.6%.
What is CELG-RI's earnings growth rate?
CELG-RI compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: +5.5%, 5-Year: N/A, 10-Year: +13.6%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1989 to 2025.
What are CELG-RI's profit margins?
Bristol-Myers Squibb Company Ce net profit margin is +14.6%, operating margin is +31.4%, and gross margin is +65.9%. Margins are within a typical range for the sector. Return on Equity is +40.4%.
Is CELG-RI growing earnings?
Yes, CELG-RI earnings are accelerating — EPS growth of +178.5% exceeds the 5-year CAGR of N/A. TTM net income reached $7.3B. Earnings momentum is strengthening.
What was CELG-RI's best earnings year?
Bristol-Myers Squibb Company Ce's highest annual net income on record is $10.6B, achieved in fiscal year 2009. Earnings history on this page spans 1989 to 2025 and includes all annual and quarterly figures.
What were CELG-RI's earnings last quarter?
CELG-RI's most recent reported quarter was Q1 2026. Net income was $2.7B with diluted EPS of $1.31. For a full breakdown of all quarters, see the quarterly earnings table on this page.